drugset / Trial / NCT01913015

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01913015

RandomizedCrossoverOpen-labelTreatment

Summary

This randomized pilot phase I trial studies the side effects of dietary fat levels and abiraterone acetate uptake in patients with metastatic hormone-resistant prostate cancer. Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Eating a low or high fat diet may increase the uptake of abiraterone acetate.

Timeline

Start
2013-07
Primary completion
2014-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 250 mg Oral